Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53

Fig. 1

Up-regulation of HER2 in PDAC. A, B HER2 gene expression and protein expression in samples of tumor and adjacent normal tissue from patients with PDAC in the TCGA (left) or GSE (right) cohorts and CTPAC database. C IHC score scaled from – to +  +  + evaluated independently in tissue microarray of Renji cohort between tumor and paired adjacent normal tissue. D, E Representative IHC staining for HER2 performed in tissue microarray of Renji cohort (D) and PDX models (passage 5th) (E). IHC score scaled from −  to +  +  + indicates negative, low, medium and high expression of HER2. Statistical tests: unpaired two-tailed Student t test in (A, B), chi-square test in (C). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page